Cognetivity Neurosciences Ltd. announced the publication of its latest peer-reviewed scientific paper on its Integrated Cognitive Assessment (ICA) technology in the journal 'Multiple Sclerosis and Related Disorders'. The paper provides further significant evidence of Cognetivity's technology's validity and clinical utility for cognitive assessment in patients with neurological diseases such as multiple sclerosis (MS). The study investigated the link between subjects' performance on ICA test, the technology that drives Cognetivity's CognICATM clinical cognitive assessment tool, and brain imaging markers of the disease.

The effects of changes in brain volume (in particular deep grey matter) in patients with early relapse-remitting MS (RRMS) were related to brain performance in the form of information processing speed, as measured using CognICA. The results showed that compared to healthy subjects, people with RRMS had lower accuracy in the ICA test and higher amounts of thalamic atrophy (loss of brain volume). This means that CognICA is capable of detecting lowered brain volume and predicting the extent of disease-related damage without having to use more invasive and expensive techniques.

These results further demonstrate the advantage of the CognICA platform in providing accurate and repeatable measures of cognition in MS, a disease that has nearly 1 million sufferers in the USA alone. Earlier detection at scale allows for more effective treatment and better patient outcomes. CognICA's use of machine learning algorithms and artificial intelligence also allows the continuous monitoring and improvement of clinical decision making, leading to more personalised healthcare.